1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Following the vesting on 23 September 2018 of 25% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Ms Walmsley will receive a cash payment of £154,279.74
less applicable tax withholding in respect of 10,075.600 notional
Ordinary Shares.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.314
|
10,075.600
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
n/a (single transaction)
|
|
e)
|
Date
of thetransaction
|
2018-09-23
|
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Following the vesting on 23 September 2018 of 25% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Connor will receive a cash payment of £123,438.19
less applicable tax withholding in respect of 8,060.480 notional
Ordinary Shares.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.314
|
8,060.480
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
n/a (single transaction)
|
|
e)
|
Date
of thetransaction
|
2018-09-23
|
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Following the vesting on 23 September 2018 of 25% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Redfern will receive a cash payment of £123,438.19
less applicable tax withholding in respect of 8,060.480 notional
Ordinary Shares.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.314
|
8,060.480
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
n/a (single transaction)
|
|
e)
|
Date
of thetransaction
|
2018-09-23
|
|
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of thefinancial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of thetransaction
|
Following the vesting on 23 September 2018 of 25% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Ms Thomas will receive a cash payment of £123,438.19
less applicable tax withholding in respect of 8,060.480 notional
Ordinary Shares.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.314
|
8,060.480
|
||
d)
|
Aggregatedinformation
Aggregated volumePrice
|
n/a (single transaction)
|
|
e)
|
Date
of thetransaction
|
2018-09-23
|
|
f)
|
Place of the
transaction
|
n/a
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: September
27, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|